Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Denileukin diftitox.

D P Figgitt1, H M Lamb, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

American Journal of Clinical Dermatology
|November 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Defining the Potential for Disease Modification in Atopic Dermatitis.

American journal of clinical dermatology·2026
Same journal

Atopic Dermatitis: New Targets and Emerging Systemic Therapies.

American journal of clinical dermatology·2026
Same journal

Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.

American journal of clinical dermatology·2026
Same journal

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same journal

A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.

American journal of clinical dermatology·2026
Same journal

What's New in Photoprotection?

American journal of clinical dermatology·2026
See all related articles

Denileukin diftitox, an interleukin-2 receptor (IL-2R)-targeted toxin, shows efficacy in treating cutaneous T cell lymphoma (CTCL). This targeted therapy improved patient response rates and quality of life in clinical trials.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Cutaneous T cell lymphoma (CTCL) is an IL-2R-positive malignancy.
  • Denileukin diftitox is a novel targeted therapy combining diphtheria toxin with IL-2.

Purpose of the Study:

  • To evaluate the efficacy and safety of denileukin diftitox in patients with IL-2R-positive CTCL.
  • To assess the impact of denileukin diftitox on quality of life (QOL) in CTCL patients.

Main Methods:

  • Clinical trials involving patients with IL-2R-positive CTCL treated with denileukin diftitox at doses of 9 or 18 micrograms/kg/day for 5 days every 3 weeks.
  • A dose-ranging trial and a murine model of IL-2R-expressing malignancy were also utilized.

Main Results:

Related Experiment Videos

  • Overall response rates of 23% and 36% were observed at the specified doses, with a 37% response in a dose-ranging trial.
  • Significant improvements in QOL were noted in responders compared to baseline and non-responders.
  • Denileukin diftitox prolonged survival in a murine model.
  • Common adverse events included hypoalbuminemia, fever, hypersensitivity reactions, nausea, and asthenia. Vascular leak syndrome was also reported.

    • Conclusions:

    • Denileukin diftitox demonstrates clinical activity and improves QOL in patients with IL-2R-positive CTCL.
    • Despite antibody formation in most patients, a clinical response can still occur.
    • The safety profile includes known adverse events associated with targeted toxin therapies.